Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/103190
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Carreira, Laura D. | - |
dc.contributor.author | Matias, Francisca C. | - |
dc.contributor.author | Campos, Maria G. | - |
dc.date.accessioned | 2022-10-20T10:11:06Z | - |
dc.date.available | 2022-10-20T10:11:06Z | - |
dc.date.issued | 2022-03-29 | - |
dc.identifier.issn | 2227-9059 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/103190 | - |
dc.description.abstract | Translational research made with Cannabis sativa L. and its biocompounds provides data for some targeted diseases, as also symptoms associated with Autism Spectrum Disorders (ASDs). The main compounds ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD), are capable of modulating the endocannabinoid system since its dysregulation interferes with the pathophysiology of ASDs there are clinical evidence for its potential use in the treatment of the disease. Conventional therapy still has limitations, as it does not always treat the central symptoms, and there are many patients who do not respond to treatment, which demands more research on new therapies. Through the analysis of published literature on this topic, it is verified that cannabinoids, in particular CBD, improves symptoms associated with common comorbidities in ASDs. Some studies also demonstrate the therapeutic potential of these compounds in the treatment of central symptoms of autism. In addition, cannabinoid therapy to ASDs is associated with low adverse effects and a reduction in concomitant medication. Although it appears to be promising, it is essential to do the translation of this data into clinical research and some of its potential and critical gaps are discussed in this review pointing to large-scale and long-term clinical trials that should include more patients and homogeneous samples. | pt |
dc.language.iso | eng | pt |
dc.relation | UIDB/00313/2020 | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | cannabinoids | pt |
dc.subject | cannabidiol | pt |
dc.subject | clinical trial | pt |
dc.subject | anxiety | pt |
dc.subject | FAAH | pt |
dc.subject | social interaction | pt |
dc.subject | inflammation | pt |
dc.subject | gamma-aminobutyric acid | pt |
dc.subject | glutamate | pt |
dc.subject | neuroimaging | pt |
dc.title | Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders | pt |
dc.type | article | - |
degois.publication.firstPage | 796 | pt |
degois.publication.issue | 4 | pt |
degois.publication.title | Biomedicines | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.3390/biomedicines10040796 | pt |
degois.publication.volume | 10 | pt |
dc.date.embargo | 2022-03-29 | * |
uc.date.periodoEmbargo | 0 | pt |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | Com Texto completo | - |
crisitem.author.researchunit | CQC - Coimbra Chemistry Centre | - |
crisitem.author.parentresearchunit | Faculty of Sciences and Technology | - |
crisitem.author.orcid | 0000-0002-2403-7073 | - |
Appears in Collections: | FFUC- Artigos em Revistas Internacionais I&D CQC - Artigos em Revistas Internacionais I&D ICNAS - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Clinical-Data-on-Canabinoids-Translational-Research-in-the-Treatment-of-Autism-Spectrum-DisordersBiomedicines.pdf | 1.36 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
3
checked on Apr 29, 2024
WEB OF SCIENCETM
Citations
1
checked on Nov 15, 2022
Page view(s)
77
checked on May 7, 2024
Download(s)
191
checked on May 7, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License